The headline reads as positive (95% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › VSTM
Verastem, Inc. (VSTM) stock analysis
WEAK BUY 27% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Verastem, Inc. (VSTM) WEAK BUY with 27% confidence at a price of $9.84. That means the signals lean positive, but they are mixed, so conviction is low.
SectorHealthcare
IndustryBiotechnology
Market cap1.19B
Analysed price$9.84
Technical picture
The 14-day RSI is 65, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.5x its 20-day average; light trading makes the latest move less convincing.
Fundamentals
The company reports a profit margin of -231.6% and revenue growth of +1775.4%.
In its latest quarter it earned $-0.31 per share, which beat the $-0.45 analysts expected, with revenue +1775.4% year over year.
Wall Street's average rating is 1.1 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $17.22.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $9.84, a target of $11.59 (+17.8%) and a stop-loss at $8.08 (-17.9%).
That is a reward-to-risk ratio of about 1.0 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 4, 2026 whatever the price does.
Entry$9.84
Target$11.59
Stop-loss$8.08
Reassess byNov 4, 2026
Research notes
Verastem’s bull case centers on encouraging early multi-tumor activity and favorable tolerability for KRAS G12D inhibitor VS-7375, plus FDA alignment on a first-line pancreatic-cancer Phase 3 path; analysts’ consensus target is roughly $16.67–$17.57 versus a recent price near $10.10. The bear case is substantial execution risk: the company remains deeply loss-making, faces high R&D costs, and could require further financing if trials or commercial uptake disappoint. The major recent catalyst was the October TARGET-D 101 update and FDA trial-design alignment, alongside an approximately $250 million equity raise that improved near-term funding but created dilution. Near-term attention is likely to focus on the expected November 2 earnings report, AVMAPKI launch metrics, and additional VS-7375 clinical progress.
The model's one-paragraph read
Leans BUY — composite score +0.27 (WEAK BUY). Technicals: RSI 65.15, MACD bullish, price above SMA50. Fundamentals: margin -231.6%, revenue growth 1775.4%. Financial results: YoY revenue +1775.4%, last EPS surprise +31.1%, next earnings 2026-11-05. FinGPT news read: positive. Memory: 1 prior look(s). Internet research: Verastem’s **bull case** centers on encouraging early multi-tumor activity and favorable tolerability for KRAS G12D inhibitor VS-7375, plus FDA alignment on a first-line pancreatic-cancer Phase 3 path; analysts’ consensus target is roughly $16.67–$17.57 versus a recent price near $10.10. The **bear case** is substantial execution risk: the company remains deeply loss-making, faces high R&D costs, and could require further financing if trials or commercial uptake disappoint. The major recent catalyst was the October TARGET-D 101 update and FDA trial-design alignment, alongside an approximately $250 million equity raise that improved near-term funding but created dilution. Near-term attention is likely to focus on the expected November 2 earnings report, AVMAPKI launch metrics, and additional VS-7375 clinical progress. Suggested levels: entry $9.84, target $11.59, stop-loss $8.08, exit by 2026-11-04 (exit before next earnings (2026-11-05) -- this signal doesn't price in that report).
Past ratings for VSTM
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | WEAK BUY | 27% | $9.84 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on VSTM
Oct 29, 2026 · Verastem Must Prove Its Commercial Rebound Is Real As G12D Hopes Lift The Stock
- Oct 29, 2026: Verastem Must Prove Its Commercial Rebound Is Real As G12D Hopes Lift The Stock (Earnings Whispers)
Other Healthcare stocks we cover
ZBH · ABBV · ALC · AMGN · AMRX · ANIP · ARWR · ASTH · ATEC · ATRC · AVAH · BCRX
Frequently asked questions
Is VSTM a buy right now?
As of Oct 29, 2026, our automated model rates Verastem, Inc. (VSTM) WEAK BUY with 27% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for VSTM?
The model's most recent plan targets $11.59 with a stop-loss at $8.08, from an entry near $9.84.
When does Verastem, Inc. report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.